Prostatic preneoplasia and beyond

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1785, Issue 2, 2008, Pages 156-181

  Joshua, A M ^a,b   Evans, A ^a,c   Van der Kwast, T ^d   Zielenska, M ^e   Meeker, A K ^f   Chinnaiyan, A ^g   Squire, J A ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c TORONTO GENERAL HOSPITAL   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

^f DEPARTMENT OF PATHOLOGY   (United States)

^g UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Cancer genetics; Carcinogenesis; Disease progression; Prostatic neoplasms

Indexed keywords

ANDROGEN; GLUTATHIONE TRANSFERASE P1; HISTONE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN 14 3 3; PROTEIN P53; RETINOBLASTOMA PROTEIN; SOMATOMEDIN; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR NKX2.5; TRANSCRIPTION FACTOR NKX3.1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UVOMORULIN; WNT PROTEIN;

APOPTOSIS; CANCER GENETICS; CARCINOGENESIS; CELL INTERACTION; CHROMOSOMAL INSTABILITY; CHROMOSOME REARRANGEMENT; DISEASE COURSE; DNA METHYLATION; EPIGENETICS; GENOMIC INSTABILITY; HISTOPATHOLOGY; HUMAN; MALE; ONCOGENE; PRECANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SENESCENCE; SIGNAL TRANSDUCTION; STEM CELL; TUMOR SUPPRESSOR GENE;

ANDROGENS; CELL TRANSFORMATION, NEOPLASTIC; EPIGENESIS, GENETIC; GENES, TUMOR SUPPRESSOR; GENOMIC INSTABILITY; HUMANS; MALE; MODELS, BIOLOGICAL; PRECANCEROUS CONDITIONS; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; STROMAL CELLS; TRANSLOCATION, GENETIC;

EID: 42149122683     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2007.12.001     Document Type: Review

References (427)

1. Canadian Cancer Statistics 2007, Canadian Cancer Society National Cancer Institute of Canada. Canadian Cancer Society and National Cancer Institute of Canada (2007)
2. Cancer Facts and Figures, 2007, The American Cancer Society. The American Cancer Society (2007)
3. DeMarzo A.M., Nelson W.G., Isaacs W.B., and Epstein J.I. Pathological and molecular aspects of prostate cancer. Lancet 361 (2003) 955-964
4. Isaacs J.T., and Coffey D.S. Etiology and disease process of benign prostatic hyperplasia. Prostate, Suppl. 2 (1989) 33-50
5. Ziada A., Rosenblum M., and Crawford E.D. Benign prostatic hyperplasia: an overview. Urology 53 (1999) 1-6
6. McNeal J.E., Redwine E.A., Freiha F.S., and Stamey T.A. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am. J. Surg. Pathol. 12 (1988) 897-906
7. Qian J., Wollan P., and Bostwick D.G. The extent and multicentricity of high-grade prostatic intraepithelial neoplasia in clinically localized prostatic adenocarcinoma. Hum. Pathol. 28 (1997) 143-148
8. Sakr W.A., Grignon D.J., Crissman J.D., Heilbrun L.K., Cassin B.J., Pontes J.J., and Haas G.P. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 8 (1994) 439-443
9. Sakr W.A., Haas G.P., Cassin B.F., Pontes J.E., and Crissman J.D. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J. Urol. 150 (1993) 379-385
10. Beheshti B., Vukovic B., Marrano P., Squire J.A., and Park P.C. Resolution of genotypic heterogeneity in prostate tumors using polymerase chain reaction and comparative genomic hybridization on microdissected carcinoma and prostatic intraepithelial neoplasia foci. Cancer Genet. Cytogenet. 137 (2002) 15-22
11. Nupponen N.N., and Visakorpi T. Molecular cytogenetics of prostate cancer. Microsc. Res. Tech. 51 (2000) 456-463
12. Hughes S., Yoshimoto M., Beheshti B., Houlston R.S., Squire J.A., and Evans A. The use of whole genome amplification to study chromosomal changes in prostate cancer: insights into genome-wide signature of preneoplasia associated with cancer progression. BMC Genomics 7 (2006) 65
13. Tomlins S.A., Mehra R., Rhodes D.R., Cao X., Wang L., Dhanasekaran S.M., Kalyana-Sundaram S., Wei J.T., Rubin M.A., Pienta K.J., Shah R.B., and Chinnaiyan A.M. Integrative molecular concept modeling of prostate cancer progression. Nat. Genet. 39 (2007) 41-51
14. Bostwick D.G., and Qian J. High-grade prostatic intraepithelial neoplasia. Mod. Pathol. 17 (2004) 360-379
15. Bishara T., Ramnani D.M., and Epstein J.I. High-grade prostatic intraepithelial neoplasia on needle biopsy: risk of cancer on repeat biopsy related to number of involved cores and morphologic pattern. Am. J. Surg. Pathol. 28 (2004) 629-633
16. Kronz J.D., Allan C.H., Shaikh A.A., and Epstein J.I. Predicting cancer following a diagnosis of high-grade prostatic intraepithelial neoplasia on needle biopsy: data on men with more than one follow-up biopsy. Am. J. Surg. Pathol. 25 (2001) 1079-1085
17. Ruska K.M., Sauvageot J., and Epstein J.I. Histology and cellular kinetics of prostatic atrophy. Am. J. Surg. Pathol. 22 (1998) 1073-1077
18. Cheville J.C., and Bostwick D.G. Postatrophic hyperplasia of the prostate. A histologic mimic of prostatic adenocarcinoma. Am. J. Surg. Pathol. 19 (1995) 1068-1076
19. De Marzo A.M., Platz E.A., Sutcliffe S., Xu J., Gronberg H., Drake C.G., Nakai Y., Isaacs W.B., and Nelson W.G. Inflammation in prostate carcinogenesis. Nat. Rev. Cancer 7 (2007) 256-269
20. De Marzo A.M., DeWeese T.L., Platz E.A., Meeker A.K., Nakayama M., Epstein J.I., Isaacs W.B., and Nelson W.G. Pathological and molecular mechanisms of prostate carcinogenesis: implications for diagnosis, detection, prevention, and treatment. J. Cell. Biochem. 91 (2004) 459-477
21. Anton R.C., Kattan M.W., Chakraborty S., and Wheeler T.M. Postatrophic hyperplasia of the prostate: lack of association with prostate cancer. Am. J. Surg. Pathol. 23 (1999) 932-936
22. Billis A. Prostatic atrophy: an autopsy study of a histologic mimic of adenocarcinoma. Mod. Pathol. 11 (1998) 47-54
23. Billis A., and Magna L.A. Inflammatory atrophy of the prostate. Prevalence and significance. Arch. Pathol. Lab. Med. 127 (2003) 840-844
24. Putzi M.J., and De Marzo A.M. Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia. Urology 56 (2000) 828-832
25. Franks L.M. Atrophy and hyperplasia in the prostate proper. J. Pathol. Bacteriol. 68 (1954) 617-621
26. Liavag I. The localization of prostatic carcinoma. An autopsy study. Scand. J. Urol. Nephrol. 2 (1968) 65-71
27. Faith D., Han S., Lee D.K., Friedl A., Hicks J.L., De Marzo A.M., and Jarrard D.F. p16 is upregulated in proliferative inflammatory atrophy of the prostate. Prostate 65 (2005) 73-82
28. Nakayama M., Bennett C.J., Hicks J.L., Epstein J.I., Platz E.A., Nelson W.G., and De Marzo A.M. Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. Am. J. Pathol. 163 (2003) 923-933
29. Parsons J.K., Nelson C.P., Gage W.R., Nelson W.G., Kensler T.W., and De Marzo A.M. GSTA1 expression in normal, preneoplastic, and neoplastic human prostate tissue. Prostate 49 (2001) 30-37
30. Zha S., Gage W.R., Sauvageot J., Saria E.A., Putzi M.J., Ewing C.M., Faith D.A., Nelson W.G., De Marzo A.M., and Isaacs W.B. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res. 61 (2001) 8617-8623
31. Bethel C.R., Faith D., Li X., Guan B., Hicks J.L., Lan F., Jenkins R.B., Bieberich C.J., and De Marzo A.M. Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion. Cancer Res. 66 (2006) 10683-10690
32. Shah R., Mucci N.R., Amin A., Macoska J.A., and Rubin M.A. Postatrophic hyperplasia of the prostate gland: neoplastic precursor or innocent bystander?. Am. J. Pathol. 158 (2001) 1767-1773
33. De Marzo A.M., Marchi V.L., Epstein J.I., and Nelson W.G. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am. J. Pathol. 155 (1999) 1985-1992
34. A.M. De Marzo, E. Smearman, A.K. Meeker, T. Iwata, American Urological Association, Anaheim, California, American Urological Association, 2007.
35. van Leenders G.J., Gage W.R., Hicks J.L., van Balken B., Aalders T.W., Schalken J.A., and De Marzo A.M. Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy. Am. J. Pathol. 162 (2003) 1529-1537
36. Slaughter D.P., Southwick H.W., and Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 6 (1953) 963-968
37. Garcia S.B., Park H.S., Novelli M., and Wright N.A. Field cancerization, clonality, and epithelial stem cells: the spread of mutated clones in epithelial sheets. J. Pathol. 187 (1999) 61-81
38. Braakhuis B.J., Tabor M.P., Kummer J.A., Leemans C.R., and Brakenhoff R.H. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res. 63 (2003) 1727-1730
39. Greene D.R., Wheeler T.M., Egawa S., Dunn J.K., and Scardino P.T. A comparison of the morphological features of cancer arising in the transition zone and in the peripheral zone of the prostate. J. Urol. 146 (1991) 1069-1076
40. Bostwick D.G., Shan A., Qian J., Darson M., Maihle N.J., Jenkins R.B., and Cheng L. Independent origin of multiple foci of prostatic intraepithelial neoplasia: comparison with matched foci of prostate carcinoma. Cancer 83 (1998) 1995-2002
41. Ruijter E.T., Miller G.J., van de Kaa C.A., van Bokhoven A., Bussemakers M.J., Debruyne F.M., Ruiter D.J., and Schalken J.A. Molecular analysis of multifocal prostate cancer lesions. J. Pathol. 188 (1999) 271-277
42. Macintosh C.A., Stower M., Reid N., and Maitland N.J. Precise microdissection of human prostate cancers reveals genotypic heterogeneity. Cancer Res. 58 (1998) 23-28
43. Cheng L., Song S.Y., Pretlow T.G., Abdul-Karim F.W., Kung H.J., Dawson D.V., Park W.S., Moon Y.W., Tsai M.L., Linehan W.M., Emmert-Buck M.R., Liotta L.A., and Zhuang Z. Evidence of independent origin of multiple tumors from patients with prostate cancer. J. Natl. Cancer Inst. 90 (1998) 233-237
44. C. Gao, B. Furusato, D.G. McLeod, S. Srivastava, G. Petrovics, I.A. Sesterhenn, American Urological Association, Anaheim, California, 2007.
45. Mehra R., Han B., Tomlins S.A., Wang L., Menon A., Wasco M.J., Shen R., Montie J.E., Chinnaiyan A.M., and Shah R.B. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res. 67 (2007) 7991-7995
46. Yu Y.P., Landsittel D., Jing L., Nelson J., Ren B., Liu L., McDonald C., Thomas R., Dhir R., Finkelstein S., Michalopoulos G., Becich M., and Luo J.H. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J. Clin. Oncol. 22 (2004) 2790-2799
47. Ananthanarayanan V., Deaton R.J., Yang X.J., Pins M.R., and Gann P.H. Alpha-methylacyl-CoA racemase (AMACR) expression in normal prostatic glands and high-grade prostatic intraepithelial neoplasia (HGPIN): association with diagnosis of prostate cancer. Prostate 63 (2005) 341-346
48. Dhir R., Vietmeier B., Arlotti J., Acquafondata M., Landsittel D., Masterson R., and Getzenberg R.H. Early identification of individuals with prostate cancer in negative biopsies. J. Urol. 171 (2004) 1419-1423
49. Ayala G., Thompson T., Yang G., Frolov A., Li R., Scardino P., Ohori M., Wheeler T., and Harper W. High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin. Cancer Res. 10 (2004) 6572-6578
50. Montironi R., Hamilton P.W., Scarpelli M., Thompson D., and Bartels P.H. Subtle morphological and molecular changes in normal-looking epithelium in prostates with prostatic intraepithelial neoplasia or cancer. Eur. Urol. 35 (1999) 468-473
51. Ananthanarayanan V., Deaton R.J., Yang X.J., Pins M.R., and Gann P.H. Alteration of proliferation and apoptotic markers in normal and premalignant tissue associated with prostate cancer. BMC Cancer 6 (2006) 73
52. Bartels P.H., da Silva V.D., Montironi R., Hamilton P.W., Thompson D., Vaught L., and Bartels H.G. Chromatin texture signatures in nuclei from prostate lesions. Anal. Quant. Cytol. Histol. 20 (1998) 407-416
53. Hanson J.A., Gillespie J.W., Grover A., Tangrea M.A., Chuaqui R.F., Emmert-Buck M.R., Tangrea J.A., Libutti S.K., Linehan W.M., and Woodson K.G. Gene promoter methylation in prostate tumor-associated stromal cells. J. Natl. Cancer Inst. 98 (2006) 255-261
54. Joshua A.M., Vukovic B., Braude I., Hussein S., Zielenska M., Srigley J., Evans A., and Squire J.A. Telomere attrition in isolated high-grade prostatic intraepithelial neoplasia and surrounding stroma is predictive of prostate cancer. Neoplasia 9 (2007) 81-89
55. Cavalieri E.L., Devanesan P., Bosland M.C., Badawi A.F., and Rogan E.G. Catechol estrogen metabolites and conjugates in different regions of the prostate of Noble rats treated with 4-hydroxyestradiol: implications for estrogen-induced initiation of prostate cancer. Carcinogenesis 23 (2002) 329-333
56. Laczko I., Hudson D.L., Freeman A., Feneley M.R., and Masters J.R. Comparison of the zones of the human prostate with the seminal vesicle: morphology, immunohistochemistry, and cell kinetics. Prostate 62 (2005) 260-266
57. Pardal R., Clarke M.F., and Morrison S.J. Applying the principles of stem-cell biology to cancer. Nat. Rev. Cancer 3 (2003) 895-902
58. Clarke M.F., and Fuller M. Stem cells and cancer: two faces of eve. Cell 124 (2006) 1111-1115
59. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., and Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 3983-3988
60. Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., Hawkins C., Squire J., and Dirks P.B. Identification of a cancer stem cell in human brain tumors. Cancer Res. 63 (2003) 5821-5828
61. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., Henkelman R.M., Cusimano M.D., and Dirks P.B. Identification of human brain tumour initiating cells. Nature 432 (2004) 396-401
62. O'Brien C.A., Pollett A., Gallinger S., and Dick J.E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445 (2007) 106-110
63. Tang D.G., Patrawala L., Calhoun T., Bhatia B., Choy G., Schneider-Broussard R., and Jeter C. Prostate cancer stem/progenitor cells: identification, characterization, and implications. Mol. Carcinog. 46 (2007) 1-14
64. Signoretti S., and Loda M. Defining cell lineages in the prostate epithelium. Cell Cycle 5 (2006) 138-141
65. Nagle R.B., Ahmann F.R., McDaniel K.M., Paquin M.L., Clark V.A., and Celniker A. Cytokeratin characterization of human prostatic carcinoma and its derived cell lines. Cancer Res. 47 (1987) 281-286
66. Liu A.Y., True L.D., LaTray L., Ellis W.J., Vessella R.L., Lange P.H., Higano C.S., Hood L., and van den Engh G. Analysis and sorting of prostate cancer cell types by flow cytometry. Prostate 40 (1999) 192-199
67. van Leenders G.J., and Schalken J.A. Stem cell differentiation within the human prostate epithelium: implications for prostate carcinogenesis. BJU Int. 88 Suppl 2 (2001) 35-42 discussion 49-50
68. Verhagen A.P., Ramaekers F.C., Aalders T.W., Schaafsma H.E., Debruyne F.M., and Schalken J.A. Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer. Cancer Res. 52 (1992) 6182-6187
69. De Marzo A.M., Nelson W.G., Meeker A.K., and Coffey D.S. Stem cell features of benign and malignant prostate epithelial cells. J. Urol. 160 (1998) 2381-2392
70. Bonkhoff H., and Remberger K. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate 28 (1996) 98-106
71. Litvinov I.V., De Marzo A.M., and Isaacs J.T. Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling?. J. Clin. Endocrinol. Metab. 88 (2003) 2972-2982
72. Richardson G.D., Robson C.N., Lang S.H., Neal D.E., Maitland N.J., and Collins A.T. CD133, a novel marker for human prostatic epithelial stem cells. J. Cell Sci. 117 (2004) 3539-3545
73. Collins A.T., and Maitland N.J. Prostate cancer stem cells. Eur. J. Cancer 42 (2006) 1213-1218
74. Lawson D.A., and Witte O.N. Stem cells in prostate cancer initiation and progression. J. Clin. Invest. 117 (2007) 2044-2050
75. Maitland N.J., and Collins A. A tumour stem cell hypothesis for the origins of prostate cancer. BJU Int. 96 (2005) 1219-1223
76. Taipale J., and Beachy P.A. The Hedgehog and Wnt signalling pathways in cancer. Nature 411 (2001) 349-354
77. Liu S., Dontu G., and Wicha M.S. Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res. 7 (2005) 86-95
78. Glinsky G.V., Berezovska O., and Glinskii A.B. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J. Clin. Invest. 115 (2005) 1503-1521
79. Verras M., and Sun Z. Roles and regulation of Wnt signaling and beta-catenin in prostate cancer. Cancer Lett. 237 (2006) 22-32
80. Thiyagarajan S., Bhatia N., Reagan-Shaw S., Cozma D., Thomas-Tikhonenko A., Ahmad N., and Spiegelman V.S. Role of GLI2 transcription factor in growth and tumorigenicity of prostate cells. Cancer Res. 67 (2007) 10642-10646
81. Kasper M., Regl G., Frischauf A.M., and Aberger F. GLI transcription factors: mediators of oncogenic Hedgehog signalling. Eur. J. Cancer 42 (2006) 437-445
82. Hooper J.E., and Scott M.P. Communicating with Hedgehogs. Nat. Rev., Mol. Cell Biol. 6 (2005) 306-317
83. Barnett D.H., Huang H.Y., Wu X.R., Laciak R., Shapiro E., and Bushman W. The human prostate expresses sonic hedgehog during fetal development. J. Urol. 168 (2002) 2206-2210
84. Fan L., Pepicelli C.V., Dibble C.C., Catbagan W., Zarycki J.L., Laciak R., Gipp J., Shaw A., Lamm M.L., Munoz A., Lipinski R., Thrasher J.B., and Bushman W. Hedgehog signaling promotes prostate xenograft tumor growth. Endocrinology 145 (2004) 3961-3970
85. Sanchez P., Hernandez A.M., Stecca B., Kahler A.J., DeGueme A.M., Barrett A., Beyna M., Datta M.W., Datta S., and Ruiz i Altaba A. Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 12561-12566
86. Wang B.E., Shou J., Ross S., Koeppen H., De Sauvage F.J., and Gao W.Q. Inhibition of epithelial ductal branching in the prostate by sonic hedgehog is indirectly mediated by stromal cells. J. Biol. Chem. 278 (2003) 18506-18513
87. Walsh P.C. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. J. Urol. 173 (2005) 1169
88. Karhadkar S.S., Bova G.S., Abdallah N., Dhara S., Gardner D., Maitra A., Isaacs J.T., Berman D.M., and Beachy P.A. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 431 (2004) 707-712
89. Shaw A., and Bushman W. Hedgehog signaling in the prostate. J. Urol. 177 (2007) 832-838
90. Sheng T., Li C., Zhang X., Chi S., He N., Chen K., McCormick F., Gatalica Z., and Xie J. Activation of the hedgehog pathway in advanced prostate cancer. Mol. Cancer 3 (2004) 29
91. Sun J., Liu W., Adams T.S., Sun J., Li X., Turner A.R., Chang B., Kim J.W., Zheng S.L., Isaacs W.B., and Xu J. DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies. Prostate 67 (2007) 692-700
92. Wodarz A., and Nusse R. Mechanisms of Wnt signaling in development. Annu. Rev. Cell Dev. Biol. 14 (1998) 59-88
93. Yang-Snyder J., Miller J.R., Brown J.D., Lai C.J., and Moon R.T. A frizzled homolog functions in a vertebrate Wnt signaling pathway. Curr. Biol. 6 (1996) 1302-1306
94. Willert K., Shibamoto S., and Nusse R. Wnt-induced dephosphorylation of axin releases beta-catenin from the axin complex. Genes Dev. 13 (1999) 1768-1773
95. Ikeda S., Kishida S., Yamamoto H., Murai H., Koyama S., and Kikuchi A. Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. Embo J. 17 (1998) 1371-1384
96. Kobayashi M., Honma T., Matsuda Y., Suzuki Y., Narisawa R., Ajioka Y., and Asakura H. Nuclear translocation of beta-catenin in colorectal cancer. Br. J. Cancer 82 (2000) 1689-1693
97. Roose J., and Clevers H. TCF transcription factors: molecular switches in carcinogenesis. Biochim. Biophys. Acta 1424 (1999) M23-M37
98. He T.C., Sparks A.B., Rago C., Hermeking H., Zawel L., da Costa L.T., Morin P.J., Vogelstein B., and Kinzler K.W. Identification of c-MYC as a target of the APC pathway. Science 281 (1998) 1509-1512
99. Mann B., Gelos M., Siedow A., Hanski M.L., Gratchev A., Ilyas M., Bodmer W.F., Moyer M.P., Riecken E.O., Buhr H.J., and Hanski C. Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 1603-1608
100. Tetsu O., and McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398 (1999) 422-426
101. Gounari F., Signoretti S., Bronson R., Klein L., Sellers W.R., Kum J., Siermann A., Taketo M.M., von Boehmer H., and Khazaie K. Stabilization of beta-catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdifferentiation of other secretory epithelia. Oncogene 21 (2002) 4099-4107
102. de la Taille A., Rubin M.A., Chen M.W., Vacherot F., de Medina S.G., Burchardt M., Buttyan R., and Chopin D. Beta-catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells. Clin. Cancer Res. 9 (2003) 1801-1807
103. Chen G., Shukeir N., Potti A., Sircar K., Aprikian A., Goltzman D., and Rabbani S.A. Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer 101 (2004) 1345-1356
104. Truica C.I., Byers S., and Gelmann E.P. Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res. 60 (2000) 4709-4713
105. Yang F., Li X., Sharma M., Sasaki C.Y., Longo D.L., Lim B., and Sun Z. Linking beta-catenin to androgen-signaling pathway. J. Biol. Chem. 277 (2002) 11336-11344
106. Mulholland D.J., Cheng H., Reid K., Rennie P.S., and Nelson C.C. The androgen receptor can promote beta-catenin nuclear translocation independently of adenomatous polyposis coli. J. Biol. Chem. 277 (2002) 17933-17943
107. Song L.N., Coghlan M., and Gelmann E.P. Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor. Mol. Endocrinol. 18 (2004) 70-85
108. Mulholland D.J., Read J.T., Rennie P.S., Cox M.E., and Nelson C.C. Functional localization and competition between the androgen receptor and T-cell factor for nuclear beta-catenin: a means for inhibition of the Tcf signaling axis. Oncogene 22 (2003) 5602-5613
109. Cronauer M.V., Schulz W.A., Ackermann R., and Burchardt M. Effects of WNT/beta-catenin pathway activation on signaling through T-cell factor and androgen receptor in prostate cancer cell lines. Int. J. Oncol. 26 (2005) 1033-1040
110. Sharma M., Chuang W.W., and Sun Z. Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation. J. Biol. Chem. 277 (2002) 30935-30941
111. Salas T.R., Kim J., Vakar-Lopez F., Sabichi A.L., Troncoso P., Jenster G., Kikuchi A., Chen S.Y., Shemshedini L., Suraokar M., Logothetis C.J., DiGiovanni J., Lippman S.M., and Menter D.G. Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity. J. Biol. Chem. 279 (2004) 19191-19200
112. Yang X., Chen M.W., Terry S., Vacherot F., Bemis D.L., Capodice J., Kitajewski J., de la Taille A., Benson M.C., Guo Y., and Buttyan R. Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells. Oncogene 25 (2006) 3436-3444
113. Ohigashi T., Mizuno R., Nakashima J., Marumo K., and Murai M. Inhibition of Wnt signaling downregulates Akt activity and induces chemosensitivity in PTEN-mutated prostate cancer cells. Prostate 62 (2005) 61-68
114. Huang W., Chang H.Y., Fei T., Wu H., and Chen Y.G. GSK3beta mediates suppression of cyclin D2 expression by tumor suppressor PTEN. Oncogene 26 (2007) 2471-2482
115. Mulholland D.J., Dedhar S., Wu H., and Nelson C.C. PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer. Oncogene 25 (2006) 329-337
116. Iljin K., Wolf M., Edgren H., Gupta S., Kilpinen S., Skotheim R.I., Peltola M., Smit F., Verhaegh G., Schalken J., Nees M., and Kallioniemi O. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res. 66 (2006) 10242-10246
117. Li X., Deng W., Lobo-Ruppert S.M., and Ruppert J.M. Gli1 acts through Snail and E-cadherin to promote nuclear signaling by beta-catenin. Oncogene 26 (2007) 4489-4498
118. Kwabi-Addo B., Chung W., Shen L., Ittmann M., Wheeler T., Jelinek J., and Issa J.P. Age-related DNA methylation changes in normal human prostate tissues. Clin. Cancer Res. 13 (2007) 3796-3802
119. Yegnasubramanian S., Kowalski J., Gonzalgo M.L., Zahurak M., Piantadosi S., Walsh P.C., Bova G.S., De Marzo A.M., Isaacs W.B., and Nelson W.G. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res. 64 (2004) 1975-1986
120. Florl A.R., Steinhoff C., Muller M., Seifert H.H., Hader C., Engers R., Ackermann R., and Schulz W.A. Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. Br. J. Cancer 91 (2004) 985-994
121. Herceg Z. Epigenetics and cancer: towards an evaluation of the impact of environmental and dietary factors. Mutagenesis 22 (2007) 91-103
122. Aitchison A., Warren A., Neal D., and Rabbitts P. RASSF1A promoter methylation is frequently detected in both pre-malignant and non-malignant microdissected prostatic epithelial tissues. Prostate 67 (2007) 638-644
123. Henrique R., Jeronimo C., Teixeira M.R., Hoque M.O., Carvalho A.L., Pais I., Ribeiro F.R., Oliveira J., Lopes C., and Sidransky D. Epigenetic heterogeneity of high-grade prostatic intraepithelial neoplasia: clues for clonal progression in prostate carcinogenesis. Mol. Cancer Res. 4 (2006) 1-8
124. Bedford M.T., and van Helden P.D. Hypomethylation of DNA in pathological conditions of the human prostate. Cancer Res. 47 (1987) 5274-5276
125. Dodge J.E., Okano M., Dick F., Tsujimoto N., Chen T., Wang S., Ueda Y., Dyson N., and Li E. Inactivation of Dnmt3b in mouse embryonic fibroblasts results in DNA hypomethylation, chromosomal instability, and spontaneous immortalization. J. Biol. Chem. 280 (2005) 17986-17991
126. Schulz W.A., Elo J.P., Florl A.R., Pennanen S., Santourlidis S., Engers R., Buchardt M., Seifert H.H., and Visakorpi T. Genomewide DNA hypomethylation is associated with alterations on chromosome 8 in prostate carcinoma. Genes Chromosomes Cancer 35 (2002) 58-65
127. Li L.C., Carroll P.R., and Dahiya R. Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J. Natl. Cancer Inst. 97 (2005) 103-115
128. Pulukuri S.M., Estes N., Patel J., and Rao J.S. Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer. Cancer Res. 67 (2007) 930-939
129. Ogishima T., Shiina H., Breault J.E., Tabatabai L., Bassett W.W., Enokida H., Li L.C., Kawakami T., Urakami S., Ribeiro-Filho L.A., Terashima M., Fujime M., Igawa M., and Dahiya R. Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer. Clin. Cancer Res. 11 (2005) 1028-1036
130. Schulz W.A., and Hatina J. Epigenetics of prostate cancer: beyond DNA methylation. J. Cell. Mol. Med. 10 (2006) 100-125
131. Dobosy J.R., Roberts J.L., Fu V.X., and Jarrard D.F. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia. J. Urol. 177 (2007) 822-831
132. Grover A.C., Tangrea M.A., Woodson K.G., Wallis B.S., Hanson J.C., Chuaqui R.F., Gillespie J.W., Erickson H.S., Bonner R.F., Pohida T.J., Emmert-Buck M.R., and Libutti S.K. Tumor-associated endothelial cells display GSTP1 and RARbeta2 promoter methylation in human prostate cancer. J. Transl. Med. 4 (2006) 13
133. Mahajan S., and Atkins W.M. The chemistry and biology of inhibitors and pro-drugs targeted to glutathione S-transferases. Cell. Mol. Life Sci. 62 (2005) 1221-1233
134. Cheng L., Pan C.X., Zhang J.T., Zhang S., Kinch M.S., Li L., Baldridge L.A., Wade C., Hu Z., Koch M.O., Ulbright T.M., and Eble J.N. Loss of 14-3-3sigma in prostate cancer and its precursors. Clin. Cancer Res. 10 (2004) 3064-3068
135. Henrique R., Jeronimo C., Hoque M.O., Carvalho A.L., Oliveira J., Teixeira M.R., Lopes C., and Sidransky D. Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions. DNA Cell Biol. 24 (2005) 264-269
136. Wilker E.W., van Vugt M.A., Artim S.A., Huang P.H., Petersen C.P., Reinhardt H.C., Feng Y., Sharp P.A., Sonenberg N., White F.M., and Yaffe M.B. 14-3-3sigma controls mitotic translation to facilitate cytokinesis. Nature 446 (2007) 329-332
137. Yang H., Zhang Y., Zhao R., Wen Y.Y., Fournier K., Wu H.B., Yang H.Y., Diaz J., Laronga C., and Lee M.H. Negative cell cycle regulator 14-3-3sigma stabilizes p27 Kip1 by inhibiting the activity of PKB/Akt. Oncogene 25 (2006) 4585-4594
138. Hermeking H., Lengauer C., Polyak K., He T.C., Zhang L., Thiagalingam S., Kinzler K.W., and Vogelstein B. 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol. Cell 1 (1997) 3-11
139. Gao N., Zhang Z., Jiang B.H., and Shi X. Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem. Biophys. Res. Commun. 310 (2003) 1124-1132
140. Graff J.R., Gabrielson E., Fujii H., Baylin S.B., and Herman J.G. Methylation patterns of the E-cadherin 5′ CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J. Biol. Chem. 275 (2000) 2727-2732
141. Graff J.R., Herman J.G., Lapidus R.G., Chopra H., Xu R., Jarrard D.F., Isaacs W.B., Pitha P.M., Davidson N.E., and Baylin S.B. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res. 55 (1995) 5195-5199
142. Ross J.S., Figge H.L., Bui H.X., del Rosario A.D., Fisher H.A., Nazeer T., Jennings T.A., Ingle R., and Kim D.N. E-cadherin expression in prostatic carcinoma biopsies: correlation with tumor grade, DNA content, pathologic stage, and clinical outcome. Mod. Pathol. 7 (1994) 835-841
143. Richmond P.J., Karayiannakis A.J., Nagafuchi A., Kaisary A.V., and Pignatelli M. Aberrant E-cadherin and alpha-catenin expression in prostate cancer: correlation with patient survival. Cancer Res. 57 (1997) 3189-3193
144. Patra S.K., Patra A., Zhao H., and Dahiya R. DNA methyltransferase and demethylase in human prostate cancer. Mol. Carcinog. 33 (2002) 163-171
145. Yang L., Xia L., Wu D.Y., Wang H., Chansky H.A., Schubach W.H., Hickstein D.D., and Zhang Y. Molecular cloning of ESET, a novel histone H3-specific methyltransferase that interacts with ERG transcription factor. Oncogene 21 (2002) 148-152
146. Halkidou K., Gaughan L., Cook S., Leung H.Y., Neal D.E., and Robson C.N. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 59 (2004) 177-189
147. Sharma S., Vogelzang N., Wong B., Adams C., Manno P., Welbourne K., and Giraud Y. ASCO Annual Meeting Proceedings. Journal of Clinical Oncology, Atlanta, Georgia vol. 24(18S) (2006)
148. Bandyopadhyay D., Mishra A., and Medrano E.E. Overexpression of histone deacetylase 1 confers resistance to sodium butyrate-mediated apoptosis in melanoma cells through a p53-mediated pathway. Cancer Res. 64 (2004) 7706-7710
149. Lagger G., O'Carroll D., Rembold M., Khier H., Tischler J., Weitzer G., Schuettengruber B., Hauser C., Brunmeir R., Jenuwein T., and Seiser C. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. Embo J. 21 (2002) 2672-2681
150. Zhou Q., Melkoumian Z.K., Lucktong A., Moniwa M., Davie J.R., and Strobl J.S. Rapid induction of histone hyperacetylation and cellular differentiation in human breast tumor cell lines following degradation of histone deacetylase-1. J. Biol. Chem. 275 (2000) 35256-35263
151. Gaughan L., Logan I.R., Cook S., Neal D.E., and Robson C.N. Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor. J. Biol. Chem. 277 (2002) 25904-25913
152. Ito A., Kawaguchi Y., Lai C.H., Kovacs J.J., Higashimoto Y., Appella E., and Yao T.P. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. Embo J. 21 (2002) 6236-6245
153. Li X., Yin S., Meng Y., Sakr W., and Sheng S. Endogenous inhibition of histone deacetylase 1 by tumor-suppressive maspin. Cancer Res. 66 (2006) 9323-9329
154. Yin S., Lockett J., Meng Y., Biliran Jr. H., Blouse G.E., Li X., Reddy N., Zhao Z., Lin X., Anagli J., Cher M.L., and Sheng S. Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system. Cancer Res. 66 (2006) 4173-4181
155. Luo J.L., Tan W., Ricono J.M., Korchynskyi O., Zhang M., Gonias S.L.,
156. Yin S., Li X., Meng Y., Finley Jr. R.L., Sakr W., Yang H., Reddy N., and Sheng S. Tumor-suppressive maspin regulates cell response to oxidative stress by direct interaction with glutathione S-transferase. J. Biol. Chem. 280 (2005) 34985-34996
157. Bracken A.P., Kleine-Kohlbrecher D., Dietrich N., Pasini D., Gargiulo G., Beekman C., Theilgaard-Monch K., Minucci S., Porse B.T., Marine J.C., Hansen K.H., and Helin K. The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev. 21 (2007) 525-530
158. Cha T.L., Zhou B.P., Xia W., Wu Y., Yang C.C., Chen C.T., Ping B., Otte A.P., and Hung M.C. Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science 310 (2005) 306-310
159. Gil J., and Peters G. Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nat. Rev., Mol. Cell Biol. 7 (2006) 667-677
160. Yu J., Yu J., Rhodes D.R., Tomlins S.A., Cao X., Chen G., Mehra R., Wang X., Ghosh D., Shah R.B., Varambally S., Pienta K.J., and Chinnaiyan A.M. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res. 67 (2007) 10657-10663
161. Varambally S., Dhanasekaran S.M., Zhou M., Barrette T.R., Kumar-Sinha C., Sanda M.G., Ghosh D., Pienta K.J., Sewalt R.G., Otte A.P., Rubin M.A., and Chinnaiyan A.M. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419 (2002) 624-629
162. Vire E., Brenner C., Deplus R., Blanchon L., Fraga M., Didelot C., Morey L., Van Eynde A., Bernard D., Vanderwinden J.M., Bollen M., Esteller M., Di Croce L., de Launoit Y., and Fuks F. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439 (2006) 871-874
163. Fuks F., Burgers W.A., Brehm A., Hughes-Davies L., and Kouzarides T. DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat. Genet. 24 (2000) 88-91
164. Fuks F., Hurd P.J., Wolf D., Nan X., Bird A.P., and Kouzarides T. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J. Biol. Chem. 278 (2003) 4035-4040
165. Thibault A., Figg W.D., Bergan R.C., Lush R.M., Myers C.E., Tompkins A., Reed E., and Samid D. A phase II study of 5-aza-2′deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer. Tumori 84 (1998) 87-89
166. Enokida H., Shiina H., Urakami S., Igawa M., Ogishima T., Li L.C., Kawahara M., Nakagawa M., Kane C.J., Carroll P.R., and Dahiya R. Multigene methylation analysis for detection and staging of prostate cancer. Clin. Cancer Res. 11 (2005) 6582-6588
167. Rajagopalan H., Nowak M.A., Vogelstein B., and Lengauer C. The significance of unstable chromosomes in colorectal cancer. Nat. Rev. Cancer 3 (2003) 695-701
168. Ribeiro F.R., Diep C.B., Jeronimo C., Henrique R., Lopes C., Eknaes M., Lingjaerde O.C., Lothe R.A., and Teixeira M.R. Statistical dissection of genetic pathways involved in prostate carcinogenesis. Genes Chromosomes Cancer 45 (2006) 154-163
169. Saramaki O., and Visakorpi T. Chromosomal aberrations in prostate cancer. Front. Biosci. 12 (2007) 3287-3301
170. Chaib H., MacDonald J.W., Vessella R.L., Washburn J.G., Quinn J.E., Odman A., Rubin M.A., and Macoska J.A. Haploinsufficiency and reduced expression of genes localized to the 8p chromosomal region in human prostate tumors. Genes Chromosomes Cancer 37 (2003) 306-313
171. Chin K., de Solorzano C.O., Knowles D., Jones A., Chou W., Rodriguez E.G., Kuo W.L., Ljung B.M., Chew K., Myambo K., Miranda M., Krig S., Garbe J., Stampfer M., Yaswen P., Gray J.W., and Lockett S.J. In situ analyses of genome instability in breast cancer. Nat. Genet. 36 (2004) 984-988
172. Pihan G.A., Purohit A., Wallace J., Malhotra R., Liotta L., and Doxsey S.J. Centrosome defects can account for cellular and genetic changes that characterize prostate cancer progression. Cancer Res. 61 (2001) 2212-2219
173. Pihan G.A., Wallace J., Zhou Y., and Doxsey S.J. Centrosome abnormalities and chromosome instability occur together in pre-invasive carcinomas. Cancer Res. 63 (2003) 1398-1404
174. Fan R., Kumaravel T.S., Jalali F., Marrano P., Squire J.A., and Bristow R.G. Defective DNA strand break repair after DNA damage in prostate cancer cells: implications for genetic instability and prostate cancer progression. Cancer Res. 64 (2004) 8526-8533
175. Meng A.X., Jalali F., Cuddihy A., Chan N., Bindra R.S., Glazer P.M., and Bristow R.G. Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells. Radiother. Oncol. 76 (2005) 168-176
176. Kiviharju-Af Hallstrom T.M., Jaamaa S., Monkkonen M., Peltonen K., Andersson L.C., Medema R.H., Peehl D.M., and Laiho M. Human prostate epithelium lacks Wee1A-mediated DNA damage-induced checkpoint enforcement. Proc. Natl. Acad. Sci. U. S. A. 104 17 (Apr 2007) 7211-7216
177. Lobrich M., and Jeggo P.A. The impact of a negligent G2/M checkpoint on genomic instability and cancer induction. Nat. Rev., Cancer 7 (2007) 861-869
178. Tomlins S.A., Rhodes D.R., Perner S., Dhanasekaran S.M., Mehra R., Sun X.W., Varambally S., Cao X., Tchinda J., Kuefer R., Lee C., Montie J.E., Shah R.B., Pienta K.J., Rubin M.A., and Chinnaiyan A.M. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310 (2005) 644-648
179. Tomlins S.A., Mehra R., Rhodes D.R., Smith L.R., Roulston D., Helgeson B.E., Cao X., Wei J.T., Rubin M.A., Shah R.B., and Chinnaiyan A.M. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res. 66 (2006) 3396-3400
180. Soller M.J., Isaksson M., Elfving P., Soller W., Lundgren R., and Panagopoulos I. Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer 45 (2006) 717-719
181. Yoshimoto M., Joshua A.M., Chilton-Macneill S., Bayani J., Selvarajah S., Evans A.J., Zielenska M., and Squire J.A. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia 8 (2006) 465-469
182. Wang J., Cai Y., Ren C., and Ittmann M. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res. 66 (2006) 8347-8351
183. Hermans K.G., van Marion R., van Dekken H., Jenster G., van Weerden W.M., and Trapman J. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res. 66 (2006) 10658-10663
184. Cai C., Hsieh C.L., Omwancha J., Zheng Z., Chen S.Y., Baert J.L., and Shemshedini L. ETV1 is a novel androgen receptor-regulated gene that mediates prostate cancer cell invasion. Mol. Endocrinol. 21 8 (Aug 2007) 1835-1846
185. Clark J., Merson S., Jhavar S., Flohr P., Edwards S., Foster C.S., Eeles R., Martin F.L., Phillips D.H., Crundwell M., Christmas T., Thompson A., Fisher C., Kovacs G., and Cooper C.S. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene 26 18 (Apr 2007) 2667-2673
186. Liu W., Ewing C.M., Chang B.L., Li T., Sun J., Turner A.R., Dimitrov L., Zhu Y., Sun J., Kim J.W., Zheng S.L., Isaacs W.B., and Xu J. Multiple genomic alterations on 21q22 predict various TMPRSS2/ERG fusion transcripts in human prostate cancers. Genes Chromosomes Cancer 46 11 (Nov 2007) 972-980
187. Mehra R., Tomlins S.A., Shen R., Nadeem O., Wang L., Wei J.T., Pienta K.J., Ghosh D., Rubin M.A., Chinnaiyan A.M., and Shah R.B. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod. Pathol. 20 5 (May 2007) 538-544
188. Dagher R., Pham T.A., Sorbara L., Kumar S., Long L., Bernstein D., Mackall C., Raffeld M., Tsokos M., and Helman L. Molecular confirmation of Ewing sarcoma. J. Pediatr. Hematol. Oncol. 23 (2001) 221-224
189. Yoshimoto M., Ludkovski O., Bayani J., Graham C., Zielenska M., and Squire J.A. Microdeletion and concurrent translocation associated with a complex TMPRSS2:ERG prostate cancer gene fusion. Genes Chromosomes Cancer 46 9 (Sep 2007) 861-863
190. Tomlins S.A., Laxman B., Dhanasekaran S.M., Helgeson B.E., Cao X., Morris D.S., Menon A., Jing X., Cao Q., Han B., Yu J., Wang L., Montie J.E., Rubin M.A., Pienta K.J., Roulston D., Shah R.B., Varambally S., Mehra R., and Chinnaiyan A.M. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448 (2007) 595-599
191. Cerveira N., Ribeiro F.R., Peixoto A., Costa V., Henrique R., Jeronimo C., and Teixeira M.R. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia 8 (2006) 826-832
192. Clark J., Attard G., Jhavar S., Flohr P., Reid A., De-Bono J., Eeles R., Scardino P., Cuzick J., Fisher G., Parker M.D., Foster C.S., Berney D., Kovacs G., and Cooper C.S. Complex patterns of ETS gene alteration arise during cancer development in the human prostate. Oncogene (2007) (advance online publication 8 October 2007)
193. Seth A., and Watson D.K. ETS transcription factors and their emerging roles in human cancer. Eur. J. Cancer 41 (2005) 2462-2478
194. Yang L., Mei Q., Zielinska-Kwiatkowska A., Matsui Y., Blackburn M.L., Benedetti D., Krumm A.A., Taborsky Jr. G.J., and Chansky H.A. An ERG (ets-related gene)-associated histone methyltransferase interacts with histone deacetylases 1/2 and transcription co-repressors mSin3A/B. Biochem. J. 369 (2003) 651-657
195. Yi H., Fujimura Y., Ouchida M., Prasad D.D., Rao V.N., and Reddy E.S. Inhibition of apoptosis by normal and aberrant Fli-1 and erg proteins involved in human solid tumors and leukemias. Oncogene 14 (1997) 1259-1268
196. Hart A.H., Corrick C.M., Tymms M.J., Hertzog P.J., and Kola I. Human ERG is a proto-oncogene with mitogenic and transforming activity. Oncogene 10 (1995) 1423-1430
197. Im Y.H., Kim H.T., Lee C., Poulin D., Welford S., Sorensen P.H., Denny C.T., and Kim S.J. EWS-FLI1, EWS-ERG, and EWS-ETV1 oncoproteins of Ewing tumor family all suppress transcription of transforming growth factor beta type II receptor gene. Cancer Res. 60 (2000) 1536-1540
198. Zhu B., and Kyprianou N. Transforming growth factor beta and prostate cancer. Cancer Treat. Res. 126 (2005) 157-173
199. Fuchs B., Inwards C., Scully S.P., and Janknecht R. hTERT is highly expressed in Ewing's sarcoma and activated by EWS-ETS oncoproteins. Clin. Orthop. Relat. Res. (2004) 64-68
200. Cai C., Hsieh C.L., and Shemshedini L. c-Jun has multiple enhancing activities in the novel cross talk between the androgen receptor and Ets variant gene 1 in prostate cancer. Mol. Cancer Res. 5 (2007) 725-735
201. Chinnaiyan A.M. IMPaCT (Innovative Minds in Prostate Cancer Today) (September 5-8, 2007), US Army Medical Research and Material Command, Atlanta, Georgia
202. Petrovics G., Liu A., Shaheduzzaman S., Furasato B., Sun C., Chen Y., Nau M., Ravindranath L., Chen Y., Dobi A., Srikantan V., Sesterhenn I.A., McLeod D.G., Vahey M., Moul J.W., and Srivastava S. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 24 (2005) 3847-3852
203. Nam R.K., Sugar L., Wang Z., Yang W., Kitching R., Klotz L.H., Venkateswaran V., Narod S.A., and Seth A. Expression of TMPRSS2 ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol. Ther. 6 (2007)
204. Perner S., Demichelis F., Beroukhim R., Schmidt F.H., Mosquera J.M., Setlur S., Tchinda J., Tomlins S.A., Hofer M.D., Pienta K.G., Kuefer R., Vessella R., Sun X.W., Meyerson M., Lee C., Sellers W.R., Chinnaiyan A.M., and Rubin M.A. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 66 (2006) 8337-8341
205. Jenkins R.B., Nakagawa T., Kollmeyer T., Morlan B., Bergstrahl E., Davis B., Klee G., Ballman K.V., and Journal of Clinical Oncology. 2007 ASCO Annual Meeting Proceedings Part I Vol. 25 (2007), American Society of Clinical Oncology 5017 No. 18S (June 20 Supplement)
206. Attard G., Clark J., Ambroisine L., Fisher G., Kovacs G., Flohr P., Berney D., Foster C.S., Fletcher A., Gerald W.L., Moller H., Reuter V., De Bono J.S., Scardino P., Cuzick J., and Cooper C.S. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene (2007) (advance online publication 16 July 2007)
207. Demichelis F., Fall K., Perner S., Andren O., Schmidt F., Setlur S.R., Hoshida Y., Mosquera J.M., Pawitan Y., Lee C., Adami H.O., Mucci L.A., Kantoff P.W., Andersson S.O., Chinnaiyan A.M., Johansson J.E., and Rubin M.A. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26 (2007) 4596-4599
208. Kim J.H., Dhanasekaran S.M., Mehra R., Tomlins S.A., Gu W., Yu J., Kumar-Sinha C., Cao X., Dash A., Wang L., Ghosh D., Shedden K., Montie J.E., Rubin M.A., Pienta K.J., Shah R.B., and Chinnaiyan A.M. Integrative analysis of genomic aberrations associated with prostate cancer progression. Cancer Res. 67 (2007) 8229-8239
209. Konishi N., Nakamura M., Kishi M., Ishida E., Shimada K., Matsuyoshi S., Nagai H., and Emi M. Genetic mapping of allelic loss on chromosome 6q within heterogeneous prostate carcinoma. Cancer Sci. 94 (2003) 764-768
210. Nupponen N.N., Kakkola L., Koivisto P., and Visakorpi T. Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am. J. Pathol. 153 (1998) 141-148
211. Visakorpi T., Kallioniemi A.H., Syvanen A.C., Hyytinen E.R., Karhu R., Tammela T., Isola J.J., and Kallioniemi O.P. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res. 55 (1995) 342-347
212. Cher M.L., Bova G.S., Moore D.H., Small E.J., Carroll P.R., Pin S.S., Epstein J.I., Isaacs W.B., and Jensen R.H. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res. 56 (1996) 3091-3102
213. Gu X., Zerbini L.F., Otu H.H., Bhasin M., Yang Q., Joseph M.G., Grall F., Onatunde T., Correa R.G., and Libermann T.A. Reduced PDEF expression increases invasion and expression of mesenchymal genes in prostate cancer cells. Cancer Res. 67 (2007) 4219-4226
214. Oettgen P., Finger E., Sun Z., Akbarali Y., Thamrongsak U., Boltax J., Grall F., Dube A., Weiss A., Brown L., Quinn G., Kas K., Endress G., Kunsch C., and Libermann T.A. PDEF, a novel prostate epithelium-specific ets transcription factor, interacts with the androgen receptor and activates prostate-specific antigen gene expression. J. Biol. Chem. 275 (2000) 1216-1225
215. Chen H., Nandi A.K., Li X., and Bieberich C.J. NKX-3.1 interacts with prostate-derived Ets factor and regulates the activity of the PSA promoter. Cancer Res. 62 (2002) 338-340
216. Sood A.K., Saxena R., Groth J., Desouki M.M., Cheewakriangkrai C., Rodabaugh K.J., Kasyapa C.S., and Geradts J. Expression characteristics of prostate-derived Ets factor support a role in breast and prostate cancer progression. Hum. Pathol. 38 11 (Nov 2007) 1628-1638
217. Gelmann E.P. Molecular biology of the androgen receptor. J. Clin. Oncol. 20 (2002) 3001-3015
218. Hayward S.W., Rosen M.A., and Cunha G.R. Stromal-epithelial interactions in the normal and neoplastic prostate. Br. J. Urol. 79 Suppl 2 (1997) 18-26
219. Cunha G.R., Cooke P.S., and Kurita T. Role of stromal-epithelial interactions in hormonal responses. Arch. Histol. Cytol. 67 (2004) 417-434
220. Cunha G.R., Hayward S.W., Wang Y.Z., and Ricke W.A. Role of the stromal microenvironment in carcinogenesis of the prostate. Int. J. Cancer 107 (2003) 1-10
221. Cunha G.R., Hayward S.W., and Wang Y.Z. Role of stroma in carcinogenesis of the prostate. Differentiation 70 (2002) 473-485
222. Peehl D.M., and Rubin J.S. Keratinocyte growth factor: an androgen-regulated mediator of stromal-epithelial interactions in the prostate. World J. Urol. 13 (1995) 312-317
223. Cardozo C.P., Michaud C., Ost M.C., Fliss A.E., Yang E., Patterson C., Hall S.J., and Caplan A.J. C-terminal Hsp-interacting protein slows androgen receptor synthesis and reduces its rate of degradation. Arch. Biochem. Biophys. 410 (2003) 134-140
224. Chang C.Y., and McDonnell D.P. Androgen receptor-cofactor interactions as targets for new drug discovery. Trends Pharmacol. Sci. 26 (2005) 225-228
225. Dehm S.M., and Tindall D.J. Regulation of androgen receptor signaling in prostate cancer. Expert Rev. Anticancer Ther. 5 (2005) 63-74
226. Dehm S.M., and Tindall D.J. Molecular regulation of androgen action in prostate cancer. J. Cell. Biochem. 99 (2006) 333-344
227. Moehren U., Papaioannou M., Reeb C.A., Grasselli A., Nanni S., Asim M., Roell D., Prade I., Farsetti A., and Baniahmad A. Wild-type but not mutant androgen receptor inhibits expression of the hTERT telomerase subunit: a novel role of AR mutation for prostate cancer development. Faseb J. (2007) (published online before print 8 November 2007)
228. Heinlein C.A., and Chang C. The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. Mol. Endocrinol. 16 (2002) 2181-2187
229. Suzuki K., Nishiyama T., Hara N., Yamana K., Takahashi K., and Labrie F. Importance of the intracrine metabolism of adrenal androgens in androgen-dependent prostate cancer. Prostate Cancer Prostatic Dis. 10 (2007) 301-306
230. Mostaghel E.A., Page S.T., Lin D.W., Fazli L., Coleman I.M., True L.D., Knudsen B., Hess D.L., Nelson C.C., Matsumoto A.M., Bremner W.J., Gleave M.E., and Nelson P.S. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res. 67 (2007) 5033-5041
231. Wang Q., Li W., Liu X.S., Carroll J.S., Janne O.A., Keeton E.K., Chinnaiyan A.M., Pienta K.J., and Brown M. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol. Cell 27 (2007) 380-392
232. Kasper S., and Cookson M.S. Mechanisms leading to the development of hormone-resistant prostate cancer. Urol. Clin. North Am. 33 (2006) 201-210 vii.
233. Suh J., and Rabson A.B. NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon?. J. Cell. Biochem. 91 (2004) 100-117
234. Qian J., Jenkins R.B., and Bostwick D.G. Detection of chromosomal anomalies and c-myc gene amplification in the cribriform pattern of prostatic intraepithelial neoplasia and carcinoma by fluorescence in situ hybridization. Mod. Pathol. 10 (1997) 1113-1119
235. De Marzo A. IMPaCT (Innovative Minds in Prostate Cancer Today) (September 5-8, 2007), US Army Medical Research and Material Command, Atlanta, Georgia
236. Delfino F.J., Boustead J.N., Fix C., and Walker W.H. NF-kappaB and TNF-alpha stimulate androgen receptor expression in Sertoli cells. Mol. Cell. Endocrinol. 201 (2003) 1-12
237. Chen C.D., and Sawyers C.L. NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol. Cell. Biol. 22 (2002) 2862-2870
238. Foley K.P., and Eisenman R.N. Two MAD tails: what the recent knockouts of Mad1 and Mxi1 tell us about the MYC/MAX/MAD network. Biochim. Biophys. Acta 1423 (1999) M37-M47
239. Sato K., Qian J., Slezak J.M., Lieber M.M., Bostwick D.G., Bergstralh E.J., and Jenkins R.B. Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J. Natl. Cancer Inst. 91 (1999) 1574-1580
240. Sato H., Minei S., Hachiya T., Yoshida T., and Takimoto Y. Fluorescence in situ hybridization analysis of c-myc amplification in stage TNM prostate cancer in Japanese patients. Int. J. Urol. 13 (2006) 761-766
241. Reiter R.E., Sato I., Thomas G., Qian J., Gu Z., Watabe T., Loda M., and Jenkins R.B. Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer. Genes Chromosomes Cancer 27 (2000) 95-103
242. Bubendorf L., Kononen J., Koivisto P., Schraml P., Moch H., Gasser T.C., Willi N., Mihatsch M.J., Sauter G., and Kallioniemi O.P. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res. 59 (1999) 803-806
243. Williams K., Fernandez S., Stien X., Ishii K., Love H.D., Lau Y.F., Roberts R.L., and Hayward S.W. Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype. Prostate 63 (2005) 369-384
244. Gil J., Kerai P., Lleonart M., Bernard D., Cigudosa J.C., Peters G., Carnero A., and Beach D. Immortalization of primary human prostate epithelial cells by c-Myc. Cancer Res. 65 (2005) 2179-2185
245. Zhang X., Lee C., Ng P.Y., Rubin M., Shabsigh A., and Buttyan R. Prostatic neoplasia in transgenic mice with prostate-directed overexpression of the c-myc oncoprotein. Prostate 43 (2000) 278-285
246. Ellwood-Yen K., Graeber T.G., Wongvipat J., Iruela-Arispe M.L., Zhang J., Matusik R., Thomas G.V., and Sawyers C.L. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4 (2003) 223-238
247. Latil A., Vidaud D., Valeri A., Fournier G., Vidaud M., Lidereau R., Cussenot O., and Biache I. htert expression correlates with MYC over-expression in human prostate cancer. Int. J. Cancer 89 (2000) 172-176
248. Ribeiro F.R., Henrique R., Martins A.T., Jeronimo C., and Teixeira M.R. Relative copy number gain of MYC in diagnostic needle biopsies is an independent prognostic factor for prostate cancer patients. Eur. Urol. 52 (2007) 116-125
249. Yeager M., Orr N., Hayes R.B., Jacobs K.B., Kraft P., Wacholder S., Minichiello M.J., Fearnhead P., Yu K., Chatterjee N., Wang Z., Welch R., Staats B.J., Calle E.E., Feigelson H.S., Thun M.J., Rodriguez C., Albanes D., Virtamo J., Weinstein S., Schumacher F.R., Giovannucci E., Willett W.C., Cancel-Tassin G., Cussenot O., Valeri A., Andriole G.L., Gelmann E.P., Tucker M., Gerhard D.S., Fraumeni Jr. J.F., Hoover R., Hunter D.J., Chanock S.J., and Thomas G. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat. Genet. 39 (2007) 645-649
250. Gudmundsson J., Sulem P., Manolescu A., Amundadottir L.T., Gudbjartsson D., Helgason A., Rafnar T., Bergthorsson J.T., Agnarsson B.A., Baker A., Sigurdsson A., Benediktsdottir K.R., Jakobsdottir M., Xu J., Blondal T., Kostic J., Sun J., Ghosh S., Stacey S.N., Mouy M., Saemundsdottir J., Backman V.M., Kristjansson K., Tres A., Partin A.W., Albers-Akkers M.T., Godino-Ivan Marcos J., Walsh P.C., Swinkels D.W., Navarrete S., Isaacs S.D., Aben K.K., Graif T., Cashy J., Ruiz-Echarri M., Wiley K.E., Suarez B.K., Witjes J.A., Frigge M., Ober C., Jonsson E., Einarsson G.V., Mayordomo J.I., Kiemeney L.A., Isaacs W.B., Catalona W.J., Barkardottir R.B., Gulcher J.R., Thorsteinsdottir U., Kong A., and Stefansson K. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat. Genet. 39 (2007) 631-637
251. Fu V.X., Schwarze S.R., Kenowski M.L., Leblanc S., Svaren J., and Jarrard D.F. A loss of insulin-like growth factor-2 imprinting is modulated by CCCTC-binding factor down-regulation at senescence in human epithelial cells. J. Biol. Chem. 279 (2004) 52218-52226
252. Meeker A.K. Telomeres and telomerase in prostatic intraepithelial neoplasia and prostate cancer biology. Urol. Oncol. 24 (2006) 122-130
253. Moyzis R.K., Buckingham J.M., Cram L.S., Dani M., Deaven L.L., Jones M.D., Meyne J., Ratliff R.L., and Wu J.R. A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes. Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 6622-6626
254. Maser R.S., and DePinho R.A. Telomeres and the DNA damage response: why the fox is guarding the henhouse. DNA Repair (Amst) 3 (2004) 979-988
255. Kawanishi S., and Oikawa S. Mechanism of telomere shortening by oxidative stress. Ann. N.Y. Acad. Sci. 1019 (2004) 278-284
256. Ohki R., Tsurimoto T., and Ishikawa F. In vitro reconstitution of the end replication problem. Mol. Cell. Biol. 21 (2001) 5753-5766
257. Mathieu N., Pirzio L., Freulet-Marriere M.A., Desmaze C., and Sabatier L. Telomeres and chromosomal instability. Cell. Mol. Life Sci. 61 (2004) 641-656
258. Artandi S.E., Chang S., Lee S.L., Alson S., Gottlieb G.J., Chin L., and DePinho R.A. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 406 (2000) 641-645
259. Vukovic B., Park P.C., Al-Maghrabi J., Beheshti B., Sweet J., Evans A., Trachtenberg J., and Squire J. Evidence of multifocality of telomere erosion in high-grade prostatic intraepithelial neoplasia (HPIN) and concurrent carcinoma. Oncogene 22 (2003) 1978-1987
260. Braig M., Lee S., Loddenkemper C., Rudolph C., Peters A.H., Schlegelberger B., Stein H., Dorken B., Jenuwein T., and Schmitt C.A. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436 (2005) 660-665
261. Collado M., Gil J., Efeyan A., Guerra C., Schuhmacher A.J., Barradas M., Benguria A., Zaballos A., Flores J.M., Barbacid M., Beach D., and Serrano M. Tumour biology: senescence in premalignant tumours. Nature 436 (2005) 642
262. Fan C., Quan R., Feng X., Gillis A., He L., Matsumoto E.D., Salama S., Cutz J.C., Kapoor A., and Tang D. ATM activation is accompanied with earlier stages of prostate tumorigenesis. Biochim. Biophys. Acta 1763 (2006) 1090-1097
263. Chen Z., Trotman L.C., Shaffer D., Lin H.K., Dotan Z.A., Niki M., Koutcher J.A., Scher H.I., Ludwig T., Gerald W., Cordon-Cardo C., and Pandolfi P.P. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436 (2005) 725-730
264. Bettendorf O., Heine B., Kneif S., Eltze E., Semjonow A., Herbst H., Stein H., Bocker W., and Poremba C. Expression-patterns of the RNA component (hTR)and the catalytic subunit (hTERT) of human telomerase in nonneoplastic prostate tissue, prostatic intraepithelial neoplasia, and prostate cancer. Prostate 55 (2003) 99-104
265. Koeneman K.S., Pan C.X., Jin J.K., Pyle III J.M., Flanigan R.C., Shankey T.V., and Diaz M.O. Telomerase activity, telomere length, and DNA ploidy in prostatic intraepithelial neoplasia (PIN). J. Urol. 160 (1998) 1533-1539
266. Zhang W., Kapusta L.R., Slingerland J.M., and Klotz L.H. Telomerase activity in prostate cancer, prostatic intraepithelial neoplasia, and benign prostatic epithelium. Cancer Res. 58 (1998) 619-621
267. Tao W., and Levine A.J. P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 6937-6941
268. Zindy F., Eischen C.M., Randle D.H., Kamijo T., Cleveland J.L., Sherr C.J., and Roussel M.F. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 12 (1998) 2424-2433
269. Downing S.R., Russell P.J., and Jackson P. Alterations of p53 are common in early stage prostate cancer. Can. J. Urol. 10 (2003) 1924-1933
270. Petrescu A., Marzan L., Codreanu O., and Niculescu L. Immunohistochemical detection of p53 protein as a prognostic indicator in prostate carcinoma. Rom. J. Morphol. Embryol. 47 (2006) 143-146
271. Zeng L., Rowland R.G., Lele S.M., and Kyprianou N. Apoptosis incidence and protein expression of p53, TGF-beta receptor II, p27Kip1, and Smad4 in benign, premalignant, and malignant human prostate. Hum. Pathol. 35 (2004) 290-297
272. Incognito L.S., Cazares L.H., Schellhammer P.F., Kuban D.A., Van Dyk E.O., Moriarty R.P., Wright Jr. G.L., and Somers K.D. Overexpression of p53 in prostate carcinoma is associated with improved overall survival but not predictive of response to radiotherapy. Int. J. Oncol. 17 (2000) 761-769
273. Merseburger A.S., Kuczyk M.A., Serth J., Bokemeyer C., Young D.Y., Sun L., Connelly R.R., McLeod D.G., Mostofi F.K., Srivastava S.K., Stenzl A., Moul J.W., and Sesterhenn I.A. Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues. Oncol. Rep. 10 (2003) 223-228
274. Abaza R., Diaz Jr. L.K., Laskin W.B., and Pins M.R. Prognostic value of DNA ploidy, bcl-2 and p53 in localized prostate adenocarcinoma incidentally discovered at transurethral prostatectomy. J. Urol. 176 (2006) 2701-2705
275. Stackhouse G.B., Sesterhenn I.A., Bauer J.J., Mostofi F.K., Connelly R.R., Srivastava S.K., and Moul J.W. p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. J. Urol. 162 (1999) 2040-2045
276. Al-Maghrabi J.A. Chromosomal instability detected by interphase fluorescence in situ hybridization and its relation to p53 alteration in prostate carcinoma in Saudi patients. Saudi Med. J. 26 (2005) 379-384
277. Fonseca G.N., Srougi M., Leite K.R., Nesrallah L.J., and Ortiz V. The role of HER2/neu, BCL2, p53 genes and proliferating cell nuclear protein as molecular prognostic parameters in localized prostate carcinoma. Sao Paulo Med. J. 122 (2004) 124-127
278. Sasor A., Wagrowska-Danilewicz M., and Danilewicz M. Ki-67 antigen and P53 protein expression in benign and malignant prostatic lesions. Immunohistochemical quantitative study. Pol. J. Pathol. 51 (2000) 31-36
279. Kallakury B.V., Jennings T.A., Ross J.S., Breese K., Figge H.L., Fisher H.A., and Figge J. Alteration of the p53 locus in benign hyperplastic prostatic epithelium associated with high-grade prostatic adenocarcinoma. Diagn. Mol. Pathol. 3 (1994) 227-232
280. Aprikian A.G., Sarkis A.S., Fair W.R., Zhang Z.F., Fuks Z., and Cordon-Cardo C. Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. J. Urol. 151 (1994) 1276-1280
281. Henke R.P., Kruger E., Ayhan N., Hubner D., Hammerer P., and Huland H. Immunohistochemical detection of p53 protein in human prostatic cancer. J. Urol. 152 (1994) 1297-1301
282. Massenkeil G., Oberhuber H., Hailemariam S., Sulser T., Diener P.A., Bannwart F., Schafer R., and Schwarte-Waldhoff I. P53 mutations and loss of heterozygosity on chromosomes 8p, 16q, 17p, and 18q are confined to advanced prostate cancer. AntiCancer Res. 14 (1994) 2785-2790
283. Myers R.B., Oelschlager D., Srivastava S., and Grizzle W.E. Accumulation of the p53 protein occurs more frequently in metastatic than in localized prostatic adenocarcinomas. Prostate 25 (1994) 243-248
284. Mirchandani D., Zheng J., Miller G.J., Ghosh A.K., Shibata D.K., Cote R.J., and Roy-Burman P. Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. Am. J. Pathol. 147 (1995) 92-101
285. Griewe G.L., Dean R.C., Zhang W., Young D., Sesterhenn I.A., Shanmugam N., McLeod D.G., Moul J.W., and Srivastava S. p53 immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein. Prostate Cancer Prostatic Dis. 6 (2003) 281-285
286. Troester M.A., Herschkowitz J.I., Oh D.S., He X., Hoadley K.A., Barbier C.S., and Perou C.M. Gene expression patterns associated with p53 status in breast cancer. BMC Cancer 6 (2006) 276
287. Miller L.D., Smeds J., George J., Vega V.B., Vergara L., Ploner A., Pawitan Y., Hall P., Klaar S., Liu E.T., and Bergh J. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 13550-13555
288. Leite K.R., Franco M.F., Srougi M., Nesrallah L.J., Nesrallah A., Bevilacqua R.G., Darini E., Carvalho C.M., Meirelles M.I., Santana I., and Camara-Lopes L.H. Abnormal expression of MDM2 in prostate carcinoma. Mod. Pathol. 14 (2001) 428-436
289. Girinsky T., Koumenis C., Graeber T.G., Peehl D.M., and Giaccia A.J. Attenuated response of p53 and p21 in primary cultures of human prostatic epithelial cells exposed to DNA-damaging agents. Cancer Res. 55 (1995) 3726-3731
290. Gartel A.L., and Tyner A.L. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol. Cancer Ther. 1 (2002) 639-649
291. Zhou B.P., Liao Y., Xia W., Spohn B., Lee M.H., and Hung M.C. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat. Cell Biol. 3 (2001) 245-252
292. Li Y., Dowbenko D., and Lasky L.A. AKT/PKB phosphorylation of p21Cip/WAF1 enhances protein stability of p21Cip/WAF1 and promotes cell survival. J. Biol. Chem. 277 (2002) 11352-11361
293. Sherr C.J. Cancer cell cycles. Science 274 (1996) 1672-1677
294. Greenberg N.M., DeMayo F., Finegold M.J., Medina D., Tilley W.D., Aspinall J.O., Cunha G.R., Donjacour A.A., Matusik R.J., and Rosen J.M. Prostate cancer in a transgenic mouse. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 3439-3443
295. Wang Y., Hayward S.W., Donjacour A.A., Young P., Jacks T., Sage J., Dahiya R., Cardiff R.D., Day M.L., and Cunha G.R. Sex hormone-induced carcinogenesis in Rb-deficient prostate tissue. Cancer Res. 60 (2000) 6008-6017
296. Lee C.T., Capodieci P., Osman I., Fazzari M., Ferrara J., Scher H.I., and Cordon-Cardo C. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer. Clin. Cancer Res. 5 (1999) 977-983
297. Henshall S.M., Quinn D.I., Lee C.S., Head D.R., Golovsky D., Brenner P.C., Delprado W., Stricker P.D., Grygiel J.J., and Sutherland R.L. Overexpression of the cell cycle inhibitor p16INK4A in high-grade prostatic intraepithelial neoplasia predicts early relapse in prostate cancer patients. Clin. Cancer Res. 7 (2001) 544-550
298. Jarrard D.F., Modder J., Fadden P., Fu V., Sebree L., Heisey D., Schwarze S.R., and Friedl A. Alterations in the p16/pRb cell cycle checkpoint occur commonly in primary and metastatic human prostate cancer. Cancer Lett. 185 (2002) 191-199
299. Jacobs J.J., Kieboom K., Marino S., DePinho R.A., and van Lohuizen M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation
300. Sharpless N.E., and DePinho R.A. Telomeres, stem cells, senescence, and cancer. J. Clin. Invest. 113 (2004) 160-168
301. Jarrard D.F., Sarkar S., Shi Y., Yeager T.R., Magrane G., Kinoshita H., Nassif N., Meisner L., Newton M.A., Waldman F.M., and Reznikoff C.A. p16/pRb pathway alterations are required for bypassing senescence in human prostate epithelial cells. Cancer Res. 59 (1999) 2957-2964
302. Shaffer D.R., Viale A., Ishiwata R., Leversha M., Olgac S., Manova K., Satagopan J., Scher H., and Koff A. Evidence for a p27 tumor suppressive function independent of its role regulating cell proliferation in the prostate. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 210-215
303. Di Cristofano A., De Acetis M., Koff A., Cordon-Cardo C., and Pandolfi P.P. Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat. Genet. 27 (2001) 222-224
304. Gary B., Azuero R., Mohanty G.S., Bell W.C., Eltoum I.E., and Abdulkadir S.A. Interaction of Nkx3.1 and p27kip1 in prostate tumor initiation. Am. J. Pathol. 164 (2004) 1607-1614
305. Li R., Wheeler T.M., Dai H., Sayeeduddin M., Scardino P.T., Frolov A., and Ayala G.E. Biological correlates of p27 compartmental expression in prostate cancer. J. Urol. 175 (2006) 528-532
306. Revelos K., Petraki C., Gregorakis A., Scorilas A., Papanastasiou P., Tenta R., and Koutsilieris M. p27(kip1) and Ki-67 (MIB1) immunohistochemical expression in radical prostatectomy specimens of patients with clinically localized prostate cancer. In Vivo 19 (2005) 911-920
307. De Marzo A.M., Meeker A.K., Epstein J.I., and Coffey D.S. Prostate stem cell compartments: expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells. Am. J. Pathol. 153 (1998) 911-919
308. Stahl M., Dijkers P.F., Kops G.J., Lens S.M., Coffer P.J., Burgering B.M., and Medema R.H. The forkhead transcription factor FoxO regulates transcription of p27Kip1 and Bim in response to IL-2. J. Immunol. 168 (2002) 5024-5031
309. Trotman L.C., Alimonti A., Scaglioni P.P., Koutcher J.A., Cordon-Cardo C., and Pandolfi P.P. Identification of a tumour suppressor network opposing nuclear Akt function. Nature 441 (2006) 523-527
310. Halvorsen O.J., Haukaas S.A., and Akslen L.A. Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clin. Cancer Res. 9 (2003) 1474-1479
311. Gurrieri C., Capodieci P., Bernardi R., Scaglioni P.P., Nafa K., Rush L.J., Verbel D.A., Cordon-Cardo C., and Pandolfi P.P. Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J. Natl. Cancer Inst. 96 (2004) 269-279
312. Zhang H., Melamed J., Wei P., Cox K., Frankel W., Bahnson R.R., Robinson N., Pyka R., Liu Y., and Zheng P. Concordant down-regulation of proto-oncogene PML and major histocompatibility antigen HLA class I expression in high-grade prostate cancer. Cancer Immun. 3 (2003) 2
313. Fenic I., Franke F., Failing K., Steger K., and Woenckhaus J. Expression of PTEN in malignant and non-malignant human prostate tissues: comparison with p27 protein expression. J. Pathol. 203 (2004) 559-566
314. Fernandez P.L., Arce Y., Farre X., Martinez A., Nadal A., Rey M.J., Peiro N., Campo E., and Cardesa A. Expression of p27/Kip1 is down-regulated in human prostate carcinoma progression. J. Pathol. 187 (1999) 563-566
315. Pearson M., Carbone R., Sebastiani C., Cioce M., Fagioli M., Saito S., Higashimoto Y., Appella E., Minucci S., Pandolfi P.P., and Pelicci P.G. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 406 (2000) 207-210
316. Stokoe D. Pten. Curr. Biol. 11 (2001) R502
317. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J., Miliaresis C., Rodgers L., McCombie R., Bigner S.H., Giovanella B.C., Ittmann M., Tycko B., Hibshoosh H., Wigler M.H., and Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275 (1997) 1943-1947
318. Myers M.P., Stolarov J.P., Eng C., Li J., Wang S.I., Wigler M.H., Parsons R., and Tonks N.K. P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 9052-9057
319. Cantley L.C., and Neel B.G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 4240-4245
320. Vivanco I., Palaskas N., Tran C., Finn S.P., Getz G., Kennedy N.J., Jiao J., Rose J., Xie W., Loda M., Golub T., Mellinghoff I.K., Davis R.J., Wu H., and Sawyers C.L. Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell 11 (2007) 555-569
321. Datta S.R., Dudek H., Tao X., Masters S., Fu H., Gotoh Y., and Greenberg M.E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91 (1997) 231-241
322. Cardone M.H., Roy N., Stennicke H.R., Salvesen G.S., Franke T.F., Stanbridge E., Frisch S., and Reed J.C. Regulation of cell death protease caspase-9 by phosphorylation. Science 282 (1998) 1318-1321
323. Ashcroft M., Ludwig R.L., Woods D.B., Copeland T.D., Weber H.O., MacRae E.J., and Vousden K.H. Phosphorylation of HDM2 by Akt. Oncogene 21 (2002) 1955-1962
324. Graff J.R., Konicek B.W., McNulty A.M., Wang Z., Houck K., Allen S., Paul J.D., Hbaiu A., Goode R.G., Sandusky G.E., Vessella R.L., and Neubauer B.L. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J. Biol. Chem. 275 (2000) 24500-24505
325. Scott P.H., and Lawrence Jr. J.C. Attenuation of mammalian target of rapamycin activity by increased cAMP in 3T3-L1 adipocytes. J. Biol. Chem. 273 (1998) 34496-34501
326. Ozes O.N., Mayo L.D., Gustin J.A., Pfeffer S.R., Pfeffer L.M., and Donner D.B. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401 (1999) 82-85
327. Puc J., Keniry M., Li H.S., Pandita T.K., Choudhury A.D., Memeo L., Mansukhani M., Murty V.V., Gaciong Z., Meek S.E., Piwnica-Worms H., Hibshoosh H., and Parsons R. Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell 7 (2005) 193-204
328. Brunet A., Bonni A., Zigmond M.J., Lin M.Z., Juo P., Hu L.S., Anderson M.J., Arden K.C., Blenis J., and Greenberg M.E. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96 (1999) 857-868
329. Dijkers P.F., Medema R.H., Pals C., Banerji L., Thomas N.S., Lam E.W., Burgering B.M., Raaijmakers J.A., Lammers J.W., Koenderman L., and Coffer P.J. Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1). Mol. Cell. Biol. 20 (2000) 9138-9148
330. Blanco-Aparicio C., Renner O., Leal J.F., and Carnero A. Pten, More Than the Akt Pathway, Carcinogenesis (2007)
331. Shen W.H., Balajee A.S., Wang J., Wu H., Eng C., Pandolfi P.P., and Yin Y. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 128 (2007) 157-170
332. Di Cristofano A., Pesce B., Cordon-Cardo C., and Pandolfi P.P. Pten is essential for embryonic development and tumour suppression. Nat. Genet. 19 (1998) 348-355
333. Kwabi-Addo B., Giri D., Schmidt K., Podsypanina K., Parsons R., Greenberg N., and Ittmann M. Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 11563-11568
334. Abate-Shen C., Banach-Petrosky W.A., Sun X., Economides K.D., Desai N., Gregg J.P., Borowsky A.D., Cardiff R.D., and Shen M.M. Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. Cancer Res. 63 (2003) 3886-3890
335. You M.J., Castrillon D.H., Bastian B.C., O'Hagan R.C., Bosenberg M.W., Parsons R., Chin L., and DePinho R.A. Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 1455-1460
336. Ma X., Ziel-van der Made A.C., Autar B., van der Korput H.A., Vermeij M., van Duijn P., Cleutjens K.B., de Krijger R., Krimpenfort P., Berns A., van der Kwast T.H., and Trapman J. Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. Cancer Res. 65 (2005) 5730-5739
337. Chen M.L., Xu P.Z., Peng X.D., Chen W.S., Guzman G., Yang X., Di Cristofano A., Pandolfi P.P., and Hay N. The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice. Genes Dev. 20 (2006) 1569-1574
338. Dan H.C., Adli M., and Baldwin A.S. Regulation of mammalian target of rapamycin activity in PTEN-inactive prostate cancer cells by I kappa B kinase alpha. Cancer Res. 67 (2007) 6263-6269
339. Majumder P.K., Febbo P.G., Bikoff R., Berger R., Xue Q., McMahon L.M., Manola J., Brugarolas J., McDonnell T.J., Golub T.R., Loda M., Lane H.A., and Sellers W.R. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat. Med. 10 (2004) 594-601
340. Covey T.M., Edes K., and Fitzpatrick F.A. Akt activation by arachidonic acid metabolism occurs via oxidation and inactivation of PTEN tumor suppressor. Oncogene 26 (2007) 5784-5792
341. Verhagen P.C., van Duijn P.W., Hermans K.G., Looijenga L.H., van Gurp R.J., Stoop H., van der Kwast T.H., and Trapman J. The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion. J. Pathol. 208 (2006) 699-707
342. Yoshimoto M., Cutz J.C., Nuin P.A., Joshua A.M., Bayani J., Evans A.J., Zielenska M., and Squire J.A. Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. Cancer Genet. Cytogenet. 169 (2006) 128-137
343. Bedolla R., Prihoda T.J., Kreisberg J.I., Malik S.N., Krishnegowda N.K., Troyer D.A., and Ghosh P.M. Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation. Clin. Cancer Res. 13 (2007) 3860-3867
344. McMenamin M.E., Soung P., Perera S., Kaplan I., Loda M., and Sellers W.R. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res. 59 (1999) 4291-4296
345. Koksal I.T., Dirice E., Yasar D., Sanlioglu A.D., Ciftcioglu A., Gulkesen K.H., Ozes N.O., Baykara M., Luleci G., and Sanlioglu S. The assessment of PTEN tumor suppressor gene in combination with Gleason scoring and serum PSA to evaluate progression of prostate carcinoma. Urol. Oncol. 22 (2004) 307-312
346. Kreisberg J.I., Malik S.N., Prihoda T.J., Bedolla R.G., Troyer D.A., Kreisberg S., and Ghosh P.M. Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res. 64 (2004) 5232-5236
347. Schmitz M., Grignard G., Margue C., Dippel W., Capesius C., Mossong J., Nathan M., Giacchi S., Scheiden R., and Kieffer N. Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis. Int. J. Cancer 120 (2007) 1284-1292
348. Yoshimoto M., Cunha I.W., Coudry R.A., Fonseca F.P., Torres C.H., Soares F.A., and Squire J.A. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br. J. Cancer 97 (2007) 678-685
349. Sun M., Yang L., Feldman R.I., Sun X.M., Bhalla K.N., Jove R., Nicosia S.V., and Cheng J.Q. Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85alpha, androgen receptor, and Src. J. Biol. Chem. 278 (2003) 42992-43000
350. Baron S., Manin M., Beaudoin C., Leotoing L., Communal Y., Veyssiere G., and Morel L. Androgen receptor mediates non-genomic activation of phosphatidylinositol 3-OH kinase in androgen-sensitive epithelial cells. J. Biol. Chem. 279 (2004) 14579-14586
351. Sharef S., Jac J., Khan M., Amato R., and Journal of Clinical Oncology. 2006 ASCO Annual Meeting Proceedings Part I vol. 24 (2006), American Society of Clinical Oncology 14584 No. 18S (June 20 Supplement)
352. Chee K.G., Lara P.N., Longmate J., Twardowski P., Quinn D.I., Chatta G., Gandara D.R., and Journal of Clinical Oncology. 2005 ASCO Annual Meeting Proceedings vol. 23 (2005), American Society of Clinical Oncology 4642 No. 16S, Part I of II (June 1 Supplement)
353. Vocke C.D., Pozzatti R.O., Bostwick D.G., Florence C.D., Jennings S.B., Strup S.E., Duray P.H., Liotta L.A., Emmert-Buck M.R., and Linehan W.M. Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21. Cancer Res. 56 (1996) 2411-2416
354. Kim M.J., Bhatia-Gaur R., Banach-Petrosky W.A., Desai N., Wang Y., Hayward S.W., Cunha G.R., Cardiff R.D., Shen M.M., and Abate-Shen C. Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. Cancer Res. 62 (2002) 2999-3004
355. Gao H., Ouyang X., Banach-Petrosky W., Borowsky A.D., Lin Y., Kim M., Lee H., Shih W.J., Cardiff R.D., Shen M.M., and Abate-Shen C. A critical role for p27kip1 gene dosage in a mouse model of prostate carcinogenesis. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 17204-17209
356. Asatiani E., Huang W.X., Wang A., Rodriguez Ortner E., Cavalli L.R., Haddad B.R., and Gelmann E.P. Deletion, methylation, and expression of the NKX3.1 suppressor gene in primary human prostate cancer. Cancer Res. 65 (2005) 1164-1173
357. Gelmann E., and Markowski M.C. IMPaCT (Innovative Minds in Prostate Cancer Today) (September 5-8, 2007), US Army Medical Research and Material Command, Atlanta, Georgia
358. Ouyang X., DeWeese T.L., Nelson W.G., and Abate-Shen C. Loss-of-function of Nkx3.1 promotes increased oxidative damage in prostate carcinogenesis. Cancer Res. 65 (2005) 6773-6779
359. E. Asatiani, E. Ortner, E.E. Muhlbradt, H. Li, J. Ma, E.P. Gelmann, M. Stampfer, Interaction of NKX3.1 genotype and IGF-1 affect prostate cancer risk, Proc Amer Assoc Cancer Res, Volume 47, 2006, Abstract #3674, American Association for Cancer Research.
360. Bowen C., Stuart A., Ju J.H., Tuan J., Blonder J., Conrads T.P., Veenstra T.D., and Gelmann E.P. NKX3.1 homeodomain protein binds to topoisomerase I and enhances its activity. Cancer Res. 67 (2007) 455-464
361. Lei Q., Jiao J., Xin L., Chang C.J., Wang S., Gao J., Gleave M.E., Witte O.N., Liu X., and Wu H. NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. Cancer Cell 9 (2006) 367-378
362. Yan G., Fukabori Y., McBride G., Nikolaropolous S., and McKeehan W.L. Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Mol. Cell. Biol. 13 (1993) 4513-4522
363. Olumi A.F., Grossfeld G.D., Hayward S.W., Carroll P.R., Tlsty T.D., and Cunha G.R. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 59 (1999) 5002-5011
364. Chang S.M., and Chung L.W. Interaction between prostatic fibroblast and epithelial cells in culture: role of androgen. Endocrinology 125 (1989) 2719-2727
365. Stephenson R.A., Dinney C.P., Gohji K., Ordonez N.G., Killion J.J., and Fidler I.J. Metastatic model for human prostate cancer using orthotopic implantation in nude mice. J. Natl. Cancer Inst. 84 (1992) 951-957
366. Chung L.W., Baseman A., Assikis V., and Zhau H.E. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J. Urol. 173 (2005) 10-20
367. Sugimura Y., Cunha G.R., and Bigsby R.M. Androgenic induction of DNA synthesis in prostatic glands induced in the urothelium of testicular feminized (Tfm/Y) mice. Prostate 9 (1986) 217-225
368. Condon M.S., and Bosland M.C. The role of stromal cells in prostate cancer development and progression. In Vivo 13 (1999) 61-65
369. Tlsty T.D., and Hein P.W. Know thy neighbor: stromal cells can contribute oncogenic signals. Curr. Opin. Genet. Dev. 11 (2001) 54-59
370. Tuxhorn J.A., Ayala G.E., Smith M.J., Smith V.C., Dang T.D., and Rowley D.R. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin. Cancer Res. 8 (2002) 2912-2923
371. Feng X.H., and Derynck R. Specificity and versatility in tgf-beta signaling through Smads. Annu. Rev. Cell Dev. Biol. 21 (2005) 659-693
372. Guo Y., and Kyprianou N. Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis. Cancer Res. 59 (1999) 1366-1371
373. Kyprianou N. Activation of TGF-beta signalling in human prostate cancer cells suppresses tumorigenicity via deregulation of cell cycle progression and induction of caspase-1 mediated apoptosis: significance in prostate tumorigenesis. Prostate Cancer Prostatic Dis. 2 (1999) S18
374. Gajewska M., and Motyl T. IGF-binding proteins mediate TGF-beta 1-induced apoptosis in bovine mammary epithelial BME-UV1 cells. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 139 (2004) 65-75
375. Peehl D.M., and Sellers R.G. Induction of smooth muscle cell phenotype in cultured human prostatic stromal cells. Exp. Cell Res. 232 (1997) 208-215
376. Bhowmick N.A., Chytil A., Plieth D., Gorska A.E., Dumont N., Shappell S., Washington M.K., Neilson E.G., and Moses H.L. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303 (2004) 848-851
377. Gerdes M.J., Dang T.D., Larsen M., and Rowley D.R. Transforming growth factor-beta1 induces nuclear to cytoplasmic distribution of androgen receptor and inhibits androgen response in prostate smooth muscle cells. Endocrinology 139 (1998) 3569-3577
378. Verona E.V., Elkahloun A.G., Yang J., Bandyopadhyay A., Yeh I.T., and Sun L.Z. Transforming growth factor-beta signaling in prostate stromal cells supports prostate carcinoma growth by up-regulating stromal genes related to tissue remodeling. Cancer Res. 67 (2007) 5737-5746
379. Yang F., Tuxhorn J.A., Ressler S.J., McAlhany S.J., Dang T.D., and Rowley D.R. Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. Cancer Res. 65 (2005) 8887-8895
380. Guo Y., Jacobs S.C., and Kyprianou N. Down-regulation of protein and mRNA expression for transforming growth factor-beta (TGF-beta1) type I and type II receptors in human prostate cancer. Int. J. Cancer 71 (1997) 573-579
381. Zhao H., Shiina H., Greene K.L., Li L.C., Tanaka Y., Kishi H., Igawa M., Kane C.J., Carroll P., and Dahiya R. CpG methylation at promoter site-140 inactivates TGFbeta2 receptor gene in prostate cancer. Cancer 104 (2005) 44-52
382. Reynolds A.R., and Kyprianou N. Growth factor signalling in prostatic growth: significance in tumour development and therapeutic targeting. Br. J. Pharmacol. 147 Suppl 2 (2006) S144-S152
383. Bello-DeOcampo D., and Tindall D.J. TGF-betal/Smad signaling in prostate cancer. Curr. Drug Targets 4 (2003) 197-207
384. Ao M., Franco O.E., Park D., Raman D., Williams K., and Hayward S.W. Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium. Cancer Res. 67 (2007) 4244-4253
385. Jones J.I., and Clemmons D.R. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 16 (1995) 3-34
386. Meinbach D.S., and Lokeshwar B.L. Insulin-like growth factors and their binding proteins in prostate cancer: cause or consequence?. Urol. Oncol. 24 (2006) 294-306
387. Kaicer E.K., Blat C., and Harel L. IGF-I and IGF-binding proteins: stimulatory and inhibitory factors secreted by human prostatic adenocarcinoma cells. Growth Factors 4 (1991) 231-237
388. Baserga R., Peruzzi F., and Reiss K. The IGF-1 receptor in cancer biology. Int. J. Cancer 107 (2003) 873-877
389. Wetterau L.A., Francis M.J., Ma L., and Cohen P. Insulin-like growth factor I stimulates telomerase activity in prostate cancer cells. J. Clin. Endocrinol. Metab. 88 (2003) 3354-3359
390. Kaplan P.J., Mohan S., Cohen P., Foster B.A., and Greenberg N.M. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res. 59 (1999) 2203-2209
391. Miyake H., Nelson C., Rennie P.S., and Gleave M.E. Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3′-kinase pathway. Endocrinology 141 (2000) 2257-2265
392. Nickerson T., Chang F., Lorimer D., Smeekens S.P., Sawyers C.L., and Pollak M. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res. 61 (2001) 6276-6280
393. Juul A. Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Horm. IGF Res. 13 (2003) 113-170
394. Djavan B., Waldert M., Seitz C., and Marberger M. Insulin-like growth factors and prostate cancer. World J. Urol. 19 (2001) 225-233
395. Moschos S.J., and Mantzoros C.S. The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology 63 (2002) 317-332
396. Perry A.S., Loftus B., Moroose R., Lynch T.H., Hollywood D., Watson R.W., Woodson K., and Lawler M. In silico mining identifies IGFBP3 as a novel target of methylation in prostate cancer. Br. J. Cancer 96 10 (May 2007) 1587-1594
397. Williams A.C., Smartt H., H.Z. AM, Macfarlane M., Paraskeva C., and Collard T.J. Insulin-like growth factor binding protein 3 (IGFBP-3) potentiates TRAIL-induced apoptosis of human colorectal carcinoma cells through inhibition of NF-kappaB. Cell Death Differ 14 (2007) 137-145
398. Han J., Jogie-Brahim S., and Oh Y. IMPaCT (Innovative Minds in Prostate Cancer Today) (September 5-7, 2007), US Army Medical Research and Material Command, Atlanta, Georgia
399. Foster B.A., Kaplan P.J., and Greenberg N.M. Peptide growth factors and prostate cancer: new models, new opportunities. Cancer Metastasis Rev. 17 (1998) 317-324
400. Mauro L., Salerno M., Morelli C., Boterberg T., Bracke M.E., and Surmacz E. Role of the IGF-I receptor in the regulation of cell-cell adhesion: implications in cancer development and progression. J. Cell. Physiol. 194 (2003) 108-116
401. Silha J.V., Sheppard P.C., Mishra S., Gui Y., Schwartz J., Dodd J.G., and Murphy L.J. Insulin-like growth factor (IGF) binding protein-3 attenuates prostate tumor growth by IGF-dependent and IGF-independent mechanisms. Endocrinology 147 (2006) 2112-2121
402. Wu J.D., Haugk K., Woodke L., Nelson P., Coleman I., and Plymate S.R. Interaction of IGF signaling and the androgen receptor in prostate cancer progression. J. Cell. Biochem. 99 (2006) 392-401
403. Okada H., and Mak T.W. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat. Rev., Cancer 4 (2004) 592-603
404. Lassus P., Opitz-Araya X., and Lazebnik Y. Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization. Science 297 (2002) 1352-1354
405. Yuan X.J., and Whang Y.E. PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway. Oncogene 21 (2002) 319-327
406. Huang H., Cheville J.C., Pan Y., Roche P.C., Schmidt L.J., and Tindall D.J. PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression. J. Biol. Chem. 276 (2001) 38830-38836
407. Kennedy S.G., Kandel E.S., Cross T.K., and Hay N. Akt/protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondria. Mol. Cell. Biol. 19 (1999) 5800-5810
408. Khwaja A. Akt is more than just a bad kinase. Nature 401 (1999) 33-34
409. Brownawell A.M., Kops G.J., Macara I.G., and Burgering B.M. Inhibition of nuclear import by protein kinase B (Akt) regulates the subcellular distribution and activity of the forkhead transcription factor AFX. Mol. Cell. Biol. 21 (2001) 3534-3546
410. Rokhlin O.W., Bishop G.A., Hostager B.S., Waldschmidt T.J., Sidorenko S.P., Pavloff N., Kiefer M.C., Umansky S.R., Glover R.A., and Cohen M.B. Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res. 57 (1997) 1758-1768
411. Nimmanapalli R., Perkins C.L., Orlando M., O'Bryan E., Nguyen D., and Bhalla K.N. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res. 61 (2001) 759-763
412. Tolonen T.T., Tommola S., Jokinen S., Parviainen T., and Martikainen P.M. Bax and Bcl-2 are focally overexpressed in the normal epithelium of cancerous prostates. Scand. J. Urol. Nephrol. 41 (2007) 85-90
413. Haussler O., Epstein J.I., Amin M.B., Heitz P.U., and Hailemariam S. Cell proliferation, apoptosis, oncogene, and tumor suppressor gene status in adenosis with comparison to benign prostatic hyperplasia, prostatic intraepithelial neoplasia, and cancer. Hum. Pathol. 30 (1999) 1077-1086
414. Baltaci S., Orhan D., Ozer G., Tolunay O., and Gogous O. Bcl-2 proto-oncogene expression in low- and high-grade prostatic intraepithelial neoplasia. BJU Int. 85 (2000) 155-159
415. McDonnell T.J., Troncoso P., Brisbay S.M., Logothetis C., Chung L.W., Hsieh J.T., Tu S.M., and Campbell M.L. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 52 (1992) 6940-6944
416. Krajewska M., Krajewski S., Epstein J.I., Shabaik A., Sauvageot J., Song K., Kitada S., and Reed J.C. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am. J. Pathol. 148 (1996) 1567-1576
417. Stattin P., Damber J.E., Karlberg L., Nordgren H., and Bergh A. Bcl-2 immunoreactivity in prostate tumorigenesis in relation to prostatic intraepithelial neoplasia, grade, hormonal status, metastatic growth and survival. Urol. Res. 24 (1996) 257-264
418. Johnson M.I., Robinson M.C., Marsh C., Robson C.N., Neal D.E., and Hamdy F.C. Expression of Bcl-2, Bax, and p53 in high-grade prostatic intraepithelial neoplasia and localized prostate cancer: relationship with apoptosis and proliferation. Prostate 37 (1998) 223-229
419. Cheema S.K., Mishra S.K., Rangnekar V.M., Tari A.M., Kumar R., and Lopez-Berestein G. Par-4 transcriptionally regulates Bcl-2 through a WT1-binding site on the bcl-2 promoter. J. Biol. Chem. 278 (2003) 19995-20005
420. Goswami A., Burikhanov R., de Thonel A., Fujita N., Goswami M., Zhao Y., Eriksson J.E., Tsuruo T., and Rangnekar V.M. Binding and phosphorylation of par-4 by akt is essential for cancer cell survival. Mol. Cell 20 (2005) 33-44
421. Shukla S., and Gupta S. Suppression of constitutive and tumor necrosis factor alpha-induced nuclear factor (NF)-kappaB activation and induction of apoptosis by apigenin in human prostate carcinoma PC-3 cells: correlation with down-regulation of NF-kappaB-responsive genes. Clin. Cancer Res. 10 (2004) 3169-3178
422. Chakraborty M., Qiu S.G., Vasudevan K.M., and Rangnekar V.M. Par-4 drives trafficking and activation of Fas and Fasl to induce prostate cancer cell apoptosis and tumor regression. Cancer Res. 61 (2001) 7255-7263
423. McKenzie S., and Kyprianou N. Apoptosis evasion: the role of survival pathways in prostate cancer progression and therapeutic resistance. J. Cell. Biochem. 97 (2006) 18-32
424. Sastry K.S., Smith A.J., Karpova Y., Datta S.R., and Kulik G. Diverse antiapoptotic signaling pathways activated by vasoactive intestinal polypeptide, epidermal growth factor, and phosphatidylinositol 3-kinase in prostate cancer cells converge on BAD. J. Biol. Chem. 281 (2006) 20891-20901
425. Lapointe J., Li C., Higgins J.P., van de Rijn M., Bair E., Montgomery K., Ferrari M., Egevad L., Rayford W., Bergerheim U., Ekman P., DeMarzo A.M., Tibshirani R., Botstein D., Brown P.O., Brooks J.D., and Pollack J.R. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 811-816
426. Lapointe J., Li C., Giacomini C.P., Salari K., Huang S., Wang P., Ferrari M., Hernandez-Boussard T., Brooks J.D., and Pollack J.R. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res. 67 (2007) 8504-8510
427. Nelson W.G., Yegnasubramanian S., Agoston A.T., Bastian P.J., Lee B.H., Nakayama M., and De Marzo A.M. Abnormal DNA methylation, epigenetics, and prostate cancer. Front. Biosci. 12 (2007) 4254-4266